Aims: To evaluate in a real-world setting the effectiveness and tolerability of available GLP-1 RA drugs in patients with type 2 diabetes after a prolonged follow-up.
| INTRODUC TI ON
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) pharmacological class is increasingly becoming a widely prescribed therapy in type 2 diabetes (T2D) based upon a robust hypoglycaemic effect mediated through stimulation of β-cells aimed to enhance insulin secretion in a glucose-dependent manner, while simultaneously suppressing the secretion of glucagon from α-cells. Besides, GLP-1 RAs are able to prolong gastric emptying and induce satiety with a potential to reduce body weight, a major factor contributing to insulin resistance and hyperglycaemia in T2DM. 1, 2 Clinical trials have demonstrated that GLP-1 RA therapy is able to reduce glycated haemoglobin (HbA1c) by 1.0% from baseline values with a reduced risk of hypoglycaemia compared with sulfonylurea and insulin. 3, 4 Furthermore, many of these agents induce significant weight loss. 3, 4 Nevertheless, clinically meaningful differences have been described in head-to-head trials in regard of the magnitude of the effect on these outcomes associated to different drugs of the class, with a higher effect on weight and glucose reduction for liraglutide and weekly-based therapies, that is exenatide LAR and dulaglutide, as compared with daily-based ones, exenatide and lixisenatide. 5, 6 In addition to improving hyperglycaemia, GLP-1 RAs also counteract other diabetes-associated conditions, including obesity, hypertension and hyperlipidaemia. 7, 8 Furthermore, some GLP-1
RAs have demonstrated certain anti-atherosclerotic properties, as improvement of endothelial dysfunction and reduction of inflammatory markers and oxidative stress. 9 Such a comprehensive pharmacological profile is probably underlying a growing evidence for a potential cardiovascular risk reduction of the class. [10] [11] [12] [13] Indeed, a re- 
| MATERIAL AND ME THODS

| Study population
Hospital records from all patients in which a GLP-1 RA treat- 
| Outcomes and variables measured
Hospital records were used to retrospectively assess patients' char- 
| Statistical analysis
Categorical data are shown in percentages. All continuous variables were tested and proved to follow a normal distribution, being expressed as mean (± standard deviation). Two-sided homo/heterosce- and persistence on GLP-1 RA treatment. Changes in background antidiabetic medication after introduction of GLP-1 RA therapy are also described. For those patients with follow-up longer than 24 months, last available hospital visit records were included for analysis, with an average follow-up period of 39 months (±12.9, SD).
| Effectiveness and tolerability outcomes
Overall, all GLP-1 RA drugs significantly reduced baseline HbA1c with no significant differences among them ( Figure 1A) . Most of the 
| D ISCUSS I ON
To our knowledge, this study represents the longest observational retrospective analysis published to date, including all GLP-1 RA drugs available in Spain. Globally, its results confirm the long-term effectiveness and safety of treatment with this therapeutic class as per routine clinical practice in a tertiary hospital setting, despite a significantly different baseline profile of patients at baseline as compared to randomized clinical trials. Inversely, a low therapeutic adherence measured by persistence on treatment was documented, despite a low incidence of gastrointestinal adverse events.
| Baseline characteristics of patients
In our cohort, patients starting on a GLP-1 RA treatment were older, significantly more obese and their diabetes had a longer duration as compared to patients included in phase III RCTs from development programmes of liraglutide, [21] [22] [23] [24] [25] [26] exenatide LAR 27-32 and dulaglutide. 33 Overall, patients included in these trials had an average age of 55.7 years (vs 59.7 years old in our cohort), a diabetes duration of 7.2 years (vs 9.01 years in our cohort) and a baseline BMI of 32.26 kg/m 2 (vs 38.56 kg/m 2 in our cohort). Interestingly, HbA1c at baseline in phase III RCTs was rather similar to that of our cohort (8.28% vs 8.18%, respectively).
As expected from a cohort followed at a tertiary centre, complexity of treatment was high, as confirmed by a long duration of diabetes and a high proportion of patients being already on basal insulin Conversely, and based upon the same reasoning by Thong and colleagues, a BMI reduction of ≥3% was considered appropriate, for a cohort with a high baseline BMI. In this context, we found that 38.63% of patients did not reach efficacy goals for HbA1c or weight reduction, taken together.
TA B L E 3 Evolution of (A) efficacy and tolerability outcomes and (B) background antidiabetic therapy after introduction of GLP-1 RA
Gastrointestinal adverse events were self-reported by a low proportion of patients, 14.96%, most of them by the first follow-up visit, which is in line with data from RCTs and other RW studies. 6, 35, 36 Interestingly, proportion of patients who discontinued treatment coincided to a large extent with proportion of patients lacking efficacy as per our proposed definition. Globally, 37.07% of patients withdrew from GLP-1 RA treatment. These observations raise the possibility that in this cohort, lack of efficacy rather than tolerance might be the main reason for discontinuation of therapy. It is our sense that unaccomplished great expectations on weight reduction for both, patients and physicians, might underlay this withdrawal rate.
Our study has several weaknesses. in Spain, few patients with shorter follow-up on this drug have been included in the analysis. Main strengths of our study include a high number of patients followed for a long period of time. A total of 163 patients were followed for an average of 39 months, representing to our knowledge the longest follow-up period included in a RW study.
In conclusion, our long-term observational study has shown that all GLP-1 RAs effectively reduced HbA1c and weight, despite significant differences in baseline characteristics, in a large cohort of patients with type 2 diabetes with severe obesity. A high proportion of patients discontinued treatment despite a low proportion of GI side effects, probably based upon a perception of lack of effectiveness, although rejection of injectable therapy and cost may probably play an important role too. More RW studies are needed, specially aimed to disclose factors affecting lack of efficacy and treatment adherence. Physicians worldwide probably need to reconsider a high BMI rather than suboptimal HbA1c as a leading reason to introduce a GLP-1 RA agent in the treatment of type 2 diabetes.
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